
Dragoon Selects Teledyne FLIR OEM Prism Software for Long-Range Unmanned Platform Prototyping
GOLETA, Calif.--(BUSINESS WIRE)-- Teledyne FLIR OEM, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced Dragoon is using the Prism™ Supervisor and Prism SKR software for its AI-driven object detection, tracking, real-time autonomy flight control, and mission planning capabilities within its long-range unmanned platform prototypes under Project Artemis, a Defense Innovation Unit (DIU) initiative.
"We offer an ideal solution for the DIU Artemis project."
Share
Project Artemis is a program designed to evaluate and deploy long-range loitering munitions capable of operating in highly contested electromagnetic environments and in large numbers. Dragoon is one of four organizations within Project Artemis tasked to demonstrate low-cost, adaptable, long-range, unmanned aerial systems (UAS) platforms with the potential to maximize operational flexibility.
"The integration of Dragoon's Cinder unmanned aircraft—our low-cost, long-range platform—and Teledyne FLIR's OEM Prism software unlocks new, highly autonomous mission capabilities in complex environments," said Jason Douglas, co-founder of Dragoon Technology. "By combining our platform and payload with Teledyne FLIR's autonomy, we offer an ideal solution for the DIU Artemis project."
Prism SKR is a best-in-class automatic target recognition (ATR) software providing a drop-in solution for the FLIR Boson ® thermal camera module that optimally addresses the seeker requirements for the Dragoon UAS platform. It operates efficiently at the edge on low-power embedded processors and is compatible with both infrared (IR) and visible camera data. Prism SKR provides real-time target position, identification, direction of motion, and aim-point localization, guiding the platform's autonomous flight system for various operations.
In combination, Prism Supervisor further enhances mission readiness by providing end-to-end autonomy and mission oversight. It seamlessly integrates with Dragoon's onboard autopilot system to support real time decision-making capabilities and an intuitive mission-planning interface. The advanced autonomy in Prism Supervisor closes the loop between the on-board navigation subsystem and real-time AI-based observations to enhance UAS operational capabilities while reducing operator intervention and workload.
'Dragoon selecting Prism software for its Project Artemis work underscores our ability to deliver mission-critical capabilities for national defense,' said Jared Faraudo, vice president of product management and programs, Teledyne FLIR OEM. 'Prism SKR and Supervisor are purpose-built to enable Dragoon's unmanned systems to perform in demanding battlefield environments, ensuring reliable performance when it matters most.'
To learn more about Teledyne FLIR OEM, visit: www.flir.com.
To learn more about Dragoon, visit www.dragoon.tech.
This effort was sponsored by the U.S. Government under Other Transaction number HQ0845-25-9-0044 between Dragoon Technology and the Government. The U.S. Government is authorized to reproduce and distribute reprints for Governmental purposes notwithstanding any copyright notation thereon.
The views and conclusions contained herein are those of the authors and should not be interpreted as necessarily representing the official policies or endorsements, either expressed or implied, of the U.S. Government.
About Teledyne FLIR OEM
Teledyne FLIR OEM, a Teledyne Technologies company, is a world leader in intelligent sensing solutions for defense and industrial applications, with approximately 4,000 employees worldwide. Founded in 1978, the company creates advanced technologies to help professionals make better, faster decisions that save lives and livelihoods. For more information, please visit www.teledyneflir.com or follow @flir.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29-05-2025
- Yahoo
Wave Life Sciences to Present at 2025 Jefferies Global Healthcare Conference
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the 2025 Jefferies Global Healthcare Conference in New York City on Wednesday, June 4, 2025, at 4:55 p.m. ET. A live webcast of this presentation can be accessed by visiting 'Investor Events' on the Investors section of the Wave Life Sciences website: A replay of this presentation will be archived and available on the site for a limited time following the event. About Wave Life SciencesWave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave's RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave's diversified pipeline includes clinical programs in Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington's disease, and obesity, as well as several preclinical programs utilizing the company's broad RNA therapeutics toolkit. Driven by the calling to 'Reimagine Possible', Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave's science, pipeline and people, please visit and follow Wave on X (formerly Twitter) and LinkedIn. Contact:Kate RauschVP, Corporate Affairs and Investor Relations+1 617-949-4827 Investors:InvestorRelations@ Media:MediaRelations@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23-05-2025
- Yahoo
Eisai to Present E7386, Co-created by PRISM BioLab and Eisai, at the ASCO (American Society of Clinical Oncology) Annual Meeting
Abstract Released for E7386, Co-Developed Through Collaborative Research Between Eisai and PRISM TOKYO, May 22, 2025 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that the analysis of a combination study of E7386(*1), created through collaboration research with Eisai Co., Ltd. ("Eisai"), and Lenvatinib mesylate ("lenvatinib") (*2) will be presented by Eisai at the American Society of Clinical Oncology (ASCO) Congress 2025, held in Chicago, USA from May 30 to June 3, 2025. The abstract of the study has been released today. To determine the optimal dose of E7386 in combination with Lenvatinib in the open-label Phase Ib study (NCT04008797(*3)), expansion cohort of advanced endometrial cancer patients progressed following platinum-based chemotherapy and anti-PD-(L)1 immunotherapy have been implemented by Eisai and the enrollment of 30 patients was completed. By data cutoff (Oct 22, 2024), with 9 patients remaining on treatment, 30% (9 patients) showed the confirmed response (decrease of tumor size > 30%) for an overall response rate of 30.0%. Furthermore, among patients without prior Lenvatinib treatment, the overall response rate was 42.9%. Completing the enrollment of dose expansion cohort (n=30), the results confirmed promising preliminary antitumor activity of E7386 + Lenvatinib with a manageable safety profile. For the subsequent dose-optimization part for E7386 + LEN in advanced endometrial cancer, enrollment of patients had been initiated (NCT04008797). (*1) E7386 E7386 is an orally available small molecule CBP/ β-catenin inhibitor that inhibits protein-protein interactions between the transcription factor CBP and β-catenin, and regulates the Wnt signaling. E7386 achieved clinical POC (Proof of concept) in October 2021 and following clinical studies are ongoing including phase I for solid tumors as monotherapy, Phase Ib for solid tumors in combination with tyrosine kinase inhibitor Lenvatinib, Phase Ib/II for solid tumors in combination with pembrolizumab, the anti-PD-1 antibody from Merck & Co., Inc., Rahway, NJ, USA. (*2) Lenvatinib Lenvatinib is a multi-kinase inhibitor, discovered by Eisai and being co-developed and co-commercialized under a collaboration agreement with Merck & Co., Inc., Rahway, NJ, USA, which inhibits vascular endothelial growth factor receptors (VEGFRs),VEGFR1, VEGR2, VEGFR3 and fibroblast growth factor receptors (FGFRs), FGFR1, FGFR2, FGFR3, FGFR4, and other receptor tyrosine kinases, PDGFR-alpha, KIT, RET. Lenvatinib have been approved for thyroid cancer, hepatocellular carcinoma, thymic caner and renal cell carcinoma (in combination with Everolimus or pembrolizumab, the anti-PD-1 antibody from Merck & Co., Inc., Rahway, NJ, USA.). Lenvatinib is also approved for endometrium cancer in combination with pembrolizumab (*3) NCT04008797 NCT04008797 is an open-label Phase Ib study of E7386 in combination with other anticancer drug, Lenvatinib for the patients with solid tumors. The study has been implemented by Eisai in Japan, Korea, Taiwan region, US, and France determine the safety and the recommended phase 2 dose (RP2D) and also to see the pharmacokinetics and efficacy of E7386 + Lenvatinib. Enrolment of each cohort of hepatic, colon, endometrial cancers are ongoing. About PRISM BioLab PRISM BioLab is a discovery and development biotechnology company utilizing proprietary PepMetics® technology to discover orally available small molecule inhibitors of protein-protein interaction (PPI) targets and transform lives of patients suffering from cancer, autoimmune, fibrosis and other diseases. PepMetics® are a unique class of small molecules that mimic three-dimensional structures of alpha-helix and beta-turn, the peptide structures commonly found in intracellular PPI interphases and receptor-ligand interactions. By combining proprietary chemistry, know-how around PPI targets and AI-supported design, PepMetics® technology can deliver inhibitors of challenging PPI targets. The technology holds promise to expand the field of drug discovery by turning previously undruggable PPIs into targets readily druggable with small molecules and by generating oral small molecule alternatives for injectable biologics. PRISM BioLab is collaborating on new PPI targets with global and Japanese pharmaceutical companies. PepMetics® targeting CBP/beta-catenin PPIs licensed to Eisai Co., Ltd. and Ohara Pharmaceuticals Co., Ltd. are in clinical development for cancer and liver disease, respectively. View original content to download multimedia: SOURCE PRISM BioLab Co., Ltd. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22-05-2025
- Yahoo
PRISM MarketView Launches Emerging Sports Index
Emerging sports companies are reshaping the industry through innovation in team ownership, media, data analytics, and the expanding legal sports betting market NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- PRISM MarketView, a leading provider of unbiased market insight and company news, today announces the launch of its PRISM Emerging Sports Index in response to significant global growth and transformation in the sports industry. The new PRISM index tracks emerging companies elevating the industry through professional sports teams, sports media platforms, athletics data or analytics solutions, and legal sports betting or fantasy sports services. Analysts project that by 2028 the global sports market could reach over $680 billion and is expected to grow at a compound annual growth rate of 9.13% between 2022 and global sports industry is undergoing a transformation driven by digital engagement, data analytics, and the rapid growth of legal sports betting. From traditional team ownership and franchise operations to cutting-edge betting platforms and fan engagement technologies, the business of sports is becoming more dynamic. PRISM MarketView reviewed a selection of the companies set to transform the sports landscape for the next several years. Motorsport Games Inc. Motorsport Games (Nasdaq: MSGM) blends cutting-edge racing video games with dynamic esports competitions and content, delivering immersive experiences for racing enthusiasts and gamers worldwide. Most recently the company reported its first quarter financials posting net income of $1.0 million for Q1 2025, a significant improvement from a $1.7 million loss in Q1 2024, driven by reduced operating expenses and gains from settlements. The company raised $2.5 million in a private placement led by VR company Pimax and saw momentum from its Le Mans Ultimate title, with a major update planned for June. Despite improved financials and increased cash reserves, Motorsport Games continues to explore strategic options and cost-cutting initiatives to address ongoing liquidity challenges. SharpLink Gaming Inc. SharpLink Gaming, Inc. (Nasdaq: SBET) is an online performance marketing company specializing in the sports betting and iGaming industries. The company connects sports fans with licensed sportsbook and casino operators through targeted affiliate marketing strategies, utilizing state-specific web domains and advanced analytics to drive user engagement and conversions. Most recently, SharpLink priced a public offering of up to 1,530,612 shares of common stock at $2.94 per share, expecting to raise approximately $4.5 million in gross proceeds. The proceeds are intended for working capital, general corporate purposes, and other uses outlined in the filed prospectus. Sportsman's Warehouse Holdings, Inc. Sportsman's Warehouse Holdings (Nasdaq: SPWH) is a leading U.S.-based outdoor sporting goods retailer specializing in gear and apparel for hunting, fishing, camping, shooting, and other outdoor activities and sports. Founded in 1986 the company operates over 140 stores across more than 30 states, complemented by a robust e-commerce platform. Most recently the company announced Susan Sanderson as its Chief Marketing Officer, recognizing her pivotal role in driving recent business improvements since joining in July 2024. With over 20 years of experience in omni-channel retail and turnarounds, Sanderson is expected to lead the company's next phase of growth by sharpening brand strategy and enhancing customer engagement. CEO Paul Stone praised her transformative leadership and speed in elevating marketing and e-commerce operations, which have already contributed to the company's momentum. About PRISM MarketView:Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at and follow us on X. PRISM MarketView does not provide investment advice. Contact:PRISM MarketViewinfo@ A photo accompanying this announcement is available at in to access your portfolio